Lopinavir – Page 23 – Communicable Diseases Research

Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial

Randomized Controlled Trial

Published on 2020-10-012022-10-06
Journal: International journal of antimicrobial agents [Category] SARS, 진단,

Successful recovery from severe COVID-19 pneumonia after kidney transplantation: The interplay between immunosuppression and novel therapy including tocilizumab

신장 이식 후 중증 코로나19 폐렴에서 성공적으로 회복: 면역억제제와 토실리주맙을 포함한 새로운 요법 사이의 상호작용

Case Reports

Published on 2020-10-012022-09-11
Journal: Transplant infectious disease : an official journa [Category] MERS, SARS, 진단, 치료제,

Severe coronavirus disease 2019 (COVID‐19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series

Case Report

Published on 2020-09-252022-11-01
Journal: Clinical Case Reports [Category] COVID-19,

Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)

COVID-19 치료를 위한 중재: 메타 분석 및 시험 순차 분석을 통한 살아있는 체계적인 검토(The LIVING Project)

Research Article

Published on 2020-09-172022-08-13
Journal: PLoS Medicine [Category] Biochemistry, COVID-19, SARS,

[키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus Admission adverse event adverse events aggregate data meta-analyses all age group all age groups all-cause mortality assessment caused certainty certainty of evidence Clinical effect Clinical research Clinical significance clinical trials Cochrane guidelines Comparisons conducted convalescent plasma coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patients database development Dexamethasone driven by Effect Evidence evidence of experimental intervention Families GRADE high risk Hydroxychloroquine individual patient data meta-analyses individuals Infection intensive care International Intervention Intervention effects item Juul lack life Lopinavir Lopinavir–ritonavir mechanical ventilation meta-analyses Meta-analysis Network meta-analysis no effect no effects no evidence of nonserious adverse event nonserious adverse events on mechanical ventilation outbreak outcome outcomes participant Participants Patient patient data paucity of data performed Placebo Primary outcomes Quality of life random errors random-effects meta-analyses randomized clinical trial randomized clinical trials rapidly spreading disease rate ratio reduce reduced reducing Remdesivir renal replacement therapy replacement therapy Reporting Research researcher respiratory Respiratory failure review risk risk of bia risk of death risk ratio Ritonavir SARS-CoV-2 searched secondary Secondary outcomes Serious Adverse Event Serious Adverse Events severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 single trial single trial randomizing Sophie Spread standard care statistically significant systematic review systematic reviews Treatment treatment for COVID-19 treatment intervention treatment of COVID-19 treatments for COVID-19 treatments of COVID-19 Trial Trial methodology trial randomizing trial sequential analyses trial sequential analysis website with COVID-19
[DOI] 10.1371/journal.pmed.1003293 PMC 바로가기 [Article Type] Research Article

Hydroxychloroquine and dexamethasone in COVID-19: who won and who lost?

Review

Published on 2020-09-092022-11-01
Journal: Clinical and Molecular Allergy : CMA [Category] COVID-19,

[키워드] “cytokine storm” adopted alveolar anti-inflammatory drug Antiviral ARDS benefit cause CCL-2 Chloroquine Combination Control Controlled COVID-19 COVID-19 case COVID-19 patient COVID-19 treatment cytokine Cytokine storm syndrome death deaths Dexamethasone effective Efficacy Evidence Evidence Based Medicine FDA gold hospital Hospitalized hospitalized patients Hydroxychloroquine IL-12 IL-6 IL-8 immunological include indication Lopinavir Lopinavir—ritonavir lung damage mechanically ventilated NIH non-randomized offer patients hospitalized patients receiving oxygen patients with COVID-19 performed Pharmacologic provide provided RCT RCTs reduced reducing reducing mortality Remdesivir reported respiratory retrospective SARS-CoV-2 SARS-CoV-2 pneumonia service Severe case Standard the disease the WHO therapy therapy for COVID-19 TNFα Treatment treatment for COVID-19 Trial turn University of Oxford Vascular with COVID-19
[DOI] 10.1186/s12948-020-00132-7 PMC 바로가기 [Article Type] Review

Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients

신종 코로나바이러스(COVID-19) 환자 관리에 있어 파비피라비르의 유효성 및 안전성에 대한 체계적인 검토 및 메타분석

Meta-Analysis

Published on 2020-09-012022-09-11
Journal: Indian journal of pharmacology [Category] 임상, 치료제,

[키워드] 2019-nCoV infection 95% confidence interval adverse effects Analysis Antiviral Arbidol benefit calculated Clinical improvement comparable Comparative Controlled clinical trial controlled clinical trials COVID-19 Data analysis database drug drugs Effectiveness Efficacy Efficacy and safety evaluate except for Favipiravir Final final analysis FPV groups identify log Lopinavir Lopinavir/ritonavir management Meta-analysis Multiple negativity no difference nonrandomized Novel coronavirus Occurrence Odds ratio outcomes pandemic Patient Prevalence random effect model Randomized Rash Ritonavir searched Standard of care systematic review Viral was done
[DOI] 10.4103/ijp.ijp_998_20 PMC 바로가기 [Article Type] Meta-Analysis

Clinical Characteristics and Viral RNA Detection in Children With Coronavirus Disease 2019 in the Republic of Korea

2019 대한민국의 코로나바이러스 질환 아동의 임상적 특성 및 바이러스 RNA 검출

Research

Published on 2020-08-282022-09-10
Journal: JAMA Pediatrics [Category] Fulltext, MERS, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 age analyzed Asymptomatic Asymptomatic cases Asymptomatic individuals case sery Chain Reaction children children with COVID-19 clinical Clinical course clinical manifestation clinical manifestations Community conducted Confirmed coronavirus coronavirus disease Coronavirus disease 2019 country COVID-19 COVID-19 case COVID-19 transmission detection diagnosed Diagnosis exposure finding hospital Hydroxychloroquine identify Importance inapparent infections Infection infections information Isolation Laboratory Lopinavir Lopinavir-ritonavir Lower respiratory tract lower respiratory tract infections measure median nasopharyngeal no difference objective observation period Occurrence oropharyngeal swab participant Point Public health intervention Relevance respiratory Respiratory tract infections Result Ritonavir RNA SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 RNA SARS-CoV-2 RNA detection setting severe acute respiratory syndrome Coronavirus silent sputum Surveillance Symptom symptom onset symptomatic case symptomatic cases treated upper respiratory sample upper respiratory tract upper respiratory tract infections virus RNA with COVID-19
[DOI] 10.1001/jamapediatrics.2020.3988 PMC 바로가기 [Article Type] Research

Overview of the First 6 Months of Clinical Trials for COVID-19 Pharmacotherapy: The Most Studied Drugs

COVID-19 약물 요법에 대한 첫 6개월간의 임상 시험 개요: 가장 많이 연구된 약물

Review

Published on 2020-08-212022-09-11
Journal: Frontiers in Public Health [Category] 임상,

[키워드] affecting Analysis Azithromycin Biology candidate drug candidate drugs China Chloroquine clinical clinical trial clinical trial (2.172) clinical trials conditions coronavirus (2019-nCoV) COVID-19 COVID-19 (condition) COVID-19 infection defined Diagnosis drug drugs duplication duplications effective therapy Effectiveness Epidemiology excessive immune response focus global effort global efforts Host Hydroxychloroquine identify include information Ivermectin Lopinavir management Month MOST other conditions pandemic Perspective representing Ritonavir SARS-CoV-2 Spread tested therapy Tocilizumab treat Treatment Vaccine virus WHO
[DOI] 10.3389/fpubh.2020.00497 PMC 바로가기 [Article Type] Review

Periconceptional exposure to lopinavir, but not darunavir, impairs decidualization: a potential mechanism leading to poor birth outcomes in HIV-positive pregnancies

로피나비르에 대한 임신초기 노출(다루나비르 아님)은 탈락막화를 손상시킵니다: HIV 양성 임신에서 출산 결과가 좋지 않을 수 있는 잠재적 기전

Article

Published on 2020-08-012022-09-11
Journal: Human reproduction (Oxford, England) [Category] Coronavirus, 비임상,

[키워드] Activation Administered Affect age alteration Analysis Angiogenesis animal model Antiretroviral therapy approval Biomarker Biomarkers biopsy birth outcomes breath cART cause caution Cell Cell culture cells chance clinical implications clinical trial clinical trials clinically co-culture Combination complement Complement activation conception contributing to correlation COVID-19 COVID-19 pandemic Culture culture system current darunavir decidualization decrease drug candidate Drug safety dysregulation early pregnancies early pregnancy early stage early stages Effects Efficacy ELISA evaluate evaluated event Evidence evidence of Ex vivo experimental models expression Factor Factors female first trimester flow cytometry for inclusion foundation funding gestational age Health care Health care worker health care workers healthy highest highlight HIV HIV infection HIV protease inhibitor HIV protease inhibitors immune cell population immune cell populations immune dysregulation Immunohistochemical analysis immunohistochemistry impair impairment implication in vitro in vivo include Inflammation initiated lack leads Lopinavir Luminex assay Lye matter maturation mechanism media mice Migration modify mouse natural killer Natural killer cells offered once daily outcome outcomes Participation placental placentation potential mechanism pregnancies Pregnancy pregnant women prophylactically protease PROTECT quantified reduced regimen regulate reported reproductive resource Respiratory disease sacrifice Safe selective specific effect specific effects spiral spiral artery spiral artery remodeling STAT3 Stephen Support supported TANK termination of pregnancy therapeutic potential Think tank tissue transcription factor Transgender Treatment Trial trophoblast trophoblasts uterine uterine natural killer cells. Vascular viability was measured was obtained was used water were used with HIV women
[DOI] 10.1093/humrep/deaa151 PMC 바로가기 [Article Type] Article

The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-07-142022-10-29
Journal: Trials [Category] COVID-19, SARS,

[키워드] 48 hour addition Administered adverse effect allergy Alpha anticipated assumed baseline blinded to treatment block clinical Clinical outcome Comorbidity COVID-19 data management Day death determine dissemination drug interaction element eligible eligible participant enrolment evaluate evaluated excluded expected group hospital hospitalised hospitalised patient Hydroxychloroquine independent Intensive intensive care Intervention intervention arms invasive investigator investigator-initiated Laboratory Lopinavir management men New no interaction non-invasive ventilation nucleic acid number objective Open-label outcome participant Patient platform Primary outcome proportion Proportion of participant protocol provided QTC prolongation randomisation randomised randomised controlled trial receive receiving recruited reduce Registered registry representing required researcher Respiratory Support risk Ritonavir Sample size SARS-CoV-2 SARS-COV-2 infection secondary outcome sequence significance level Standard of care status stratified study drug Study protocol Tablet total sample size treated Trial two-sided unblinding ventilatory support Virological website women
[DOI] 10.1186/s13063-020-04576-9 PMC 바로가기 [Article Type] Letter